KVV E-Modules

Which of the following best describes a key difference between Cell-Cycle Specific (CCS) and Cell-Cycle Non-Specific (CCNS) agents

A: CCNS agents only target cells in the S-phase. B: CCS agents are more effective against low-growth fraction solid tumors. C: CCNS agents can act on resting (G₀) cells, making them more effective against certain solid tumors D: CCS agents cause more cardiotoxicity than CCNS agents

A patient develops irreversible dilated cardiomyopathy after several cycles of doxorubicin. This is an example of:

A: Dose-limiting toxicity B: Cumulative toxicity C: Acute hypersensitivity reaction D: Extravasation injury

Which of the following is the primary mechanism by which anthracyclines cause lethal DNA double-strand breaks?

A: Free radical generation only B: DNA intercalation alone C: Topoisomerase II poisoning D: ) Inhibition of nucleotide excision repair

A patient receiving oxaliplatin should be advised to avoid cold drinks and cold surfaces due to the risk of:

A: Nephrotoxicity B: Acute cold-induced neuropathy C: Hand-foot syndrome D: Severe myelosuppression

Which platinum analog requires aggressive pre- and post-hydration (3–4 L IV fluids plus mannitol) to prevent its dose-limiting toxicity?

A: Carboplatin B: Oxaliplatin C: Cisplatin D: Nedaplatin

The Calvert Formula (Dose = Target AUC × (GFR + 25)) is used for dosing which chemotherapeutic agent?

A: Doxorubicin B: Cisplatin C: Oxaliplatin D: Carboplatin

A patient has received a cumulative dose of doxorubicin of 500 mg/m². What monitoring is essential?

A: Serum creatinine and BUN B: Left ventricular ejection fraction (LVEF) by MUGA or echocardiogram C: Platelet count only D: Cold sensitivity testing

Which of the following toxicities is dose-limiting for carboplatin?

A: Nephrotoxicity B: Ototoxicity C: Myelosuppression (thrombocytopenia) D: Cardiotoxicity

Dexrazoxane is used in anthracycline therapy to:

A: Prevent alopecia B: Reverse myelosuppression C: Reduce cardiotoxicity by chelating iron and reducing free radical formation D: Treat extravasation necrosis

A common mechanism by which tumors become resistant to anthracyclines is:

A: Increased expression of DNA repair enzymes like NER B: Overexpression of MDR1 (P-glycoprotein) efflux pump C: Mutation of topoisomerase I D: Decreased intracellular calcium